NewsEvents

Your Yourlocation: Home > A randomized controlled study of combined inhalation of tiotropium bromide(136310-93-5) and salmeterol /fluticasone in the treatment of chronic obstructive pulmonary disease

To observe the effect of combined inhalation of tiotropium bromide(136310-93-5) and salmeterol /fluticasone on COPD, to reduce acute exacerbation of COPD and improve lung function and health status of patients.

Methods: 126 patients (92 males and 34 females) COPD patients (aged 45-71 years) were randomly divided into 4 groups: 33 cases (23 males and 10 females) were treated with random number table, (24 males and 8 females) were inoculated with salmeterol /fluticasone group (n = 24) and inhaled salmeterol /Fluticasone 50 /250μg, 2 times a day; tiotropium group of 32 patients (23 males and 9 females), inhaled tiotropium bromide powder capsules 18μg, 1 day. Treatment for 12 months; blank control group of 29 cases (22 males and 7 females). Organizational analysis of test data and analysis of program data.

Results: The clinical symptoms and health status of the three test groups were significantly improved, and the median (95% CI) of the remission drugs was 1 (0-7) times in the combination group, which was significantly higher than that in the blank control group 2 (0 ~ 11) times in the salmeterol /fluticasone group, and the difference was statistically significant (F = 4.914, P < 0.01). The mean number of acute episodes in the combination group was (0.7 ± 0.5) times, which was significantly lower than that in the blank control group (1.5 ± 0.9), salmeterol /fluticasone [(1.2 ± 0.6) times] and tiotropium bromide(136310-93-5) group [(1.1 ± 0.5) times], the difference was statistically significant (F: 8.513, P <0.01); The FEV1 of the combined treatment group was (1.19 ± 0.03) L, which was significantly higher than that before the experiment (1.09 ± 0.04) L, FEV before and after the experiment. The percentage of improved (9.5%) was also significantly higher than that of the blank control group (0.9%), the tiotropium group (8.2%) and the salmeterol /fluticasone group (6.3%) statistically significant (t = -5.024 ~ -15.58, all P <0.01).

Conclusion: Combined treatment of tiotropium bromide(136310-93-5) and salmeterol /fluticasone in the treatment of COPD can control the clinical symptoms and improve lung function, the effect is better than monotherapy, adverse reactions did not increase.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved